SAN FRANCISCO & LONDON--(BUSINESS WIRE)--Aiolos Bio, Inc. (“Aiolos” or “the Company”) today announced its launch as a clinical-stage biopharmaceutical company focused on addressing the unmet treatment ...
Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...
WALTHAM, Mass.--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the dosing of the first patients in its Phase 2 VALIANT ...
About TSLP and TSLPR BlockadeThymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where ...
Generate Biomedicines Inc. proved that enthusiasm hasn’t waned for TSLP as a target by pricing an IPO selling 25 million shares at $16 each for proceeds of $400 million. Generate’s lead compound is ...
US Study Ongoing in Asthma, Broad Potential Across Multiple Indications: Belenos’ Proof-of-Concept study of ‘512 in patients with mild-moderate Asthma in the U.S. expected to readout in 2026. Five ...
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product ...
Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of WIN378 in patients with asthma, with a first data readout expected in mid-2026 WIN378 has the potential to be the ...
The University of Pennsylvania looking for a diabetes treatment have accidentally developed an innovative, even revolutionary treatment for weight loss. Treating obese mice with the cytokine known as ...
Treating obese mice with the cytokine known as TSLP led to significant abdominal fat and weight loss compared to controls. The animal model findings support the possibility that increasing sebum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results